Wednesday, April 10, 2019, Anaheim, California, 11:15 AM – 12:45 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A 6-Part CNE Symposia Series Held During the ONS 44th Annual Congress

PART 1 — Gastrointestinal Cancers

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room:
Grand Ballroom E-K (Lobby Level)
10:45 AM – 11:15 AM
Registration and Lunch Buffet

11:15 AM – 12:45 PM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Jessica Mitchell, RN, CNP, MPH
Assistant Professor of Oncology
Mayo College of Medicine
Rochester, Minnesota

Eileen M O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head
Hepatopancreaticobiliary/Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director

David M Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Philip A Philip, MD, PhD
Kathryn Cramer Endowed Chair in Cancer Research
Professor of Oncology and Pharmacology
Leader, GI and Neuroendocrine Oncology
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Amanda Wagner, APRN-CNP, AOCNP
The Arthur G James Cancer Hospital
Martha Morehouse Medical Plaza
GI Medical Oncology
Columbus, Ohio

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a satellite symposium supported by Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck and Taiho Oncology Inc during the Oncology Nursing Society’s (ONS) 44th Annual Congress, April 11-14, 2019 in Anaheim, California. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
10:45 AM – 11:15 AM — Registration and Lunch Buffet
11:15 AM – 12:45 PM — Educational Program

Module 1: Approved and Emerging Treatment Approaches for Metastatic Hepatocellular Carcinoma (HCC)


  • Local treatment approaches for HCC: liver resection, transarterial chemoembolization, radiofrequency ablation
  • Efficacy and safety outcomes with lenvatinib as first-line therapy for unresectable HCC; recent FDA approval of lenvatinib and patient selection for its use in routine practice
  • Data informing the FDA approval and clinical use of regorafenib for patients with disease progression on sorafenib; optimal starting dose as second-line therapy
  • Major efficacy and tolerability findings leading to the recent FDA approval of cabozantinib for patients who have experienced disease progression on sorafenib
  • Available efficacy and safety results from pivotal clinical trials of nivolumab and pembrolizumab for patients with disease progression on sorafenib; factors guiding the use of immunotherapy versus targeted therapy for these patients
  • Key findings with second-line ramucirumab for patients with progressive HCC and elevated alpha-fetoprotein levels

Module 2: Optimal Sequence and Selection of Systemic Therapy for Locally Advanced and Metastatic Gastric, Gastroesophageal Junction (GEJ) and Esophageal Cancer


  • Integration of ramucirumab into current clinical algorithms for metastatic gastric/GEJ cancer; impact, if any, of age, performance status, prior therapeutic exposure and comorbidities on its use as second-line therapy
  • Management of hypertension and other side effects of ramucirumab
  • Research supporting the FDA approval of pembrolizumab for recurrent or advanced gastric/GEJ adenocarcinoma with a PD-L1 combined positive score (CPS) ≥1 after 2 or more lines of chemotherapy and, if appropriate, HER2-targeted therapy; clinical and research implications of the negative Phase III trial results
  • Results with pembrolizumab versus single-agent chemotherapy as second-line treatment for locally advanced or metastatic esophageal or esophagogastric junction carcinoma
  • Supportive care approaches to ameliorate side effects associated with anti-PD-1/PD-L1 antibodies
  • Data supporting the recent FDA approval of TAS-102 for patients with heavily pretreated metastatic gastric cancer; practical implementation in clinical practice

Module 3: Long-Term Management of Metastatic Colorectal Cancer (mCRC)


  • Indications for biomarker testing in mCRC (eg, MSI, RAS, BRAF, HER2); correlation of tumor location with long-term outcomes and emerging data linking tumor sidedness to response to specific therapies
  • Clinical implications of trials evaluating the earlier use of regorafenib and alternative dosing strategies with that agent
  • Optimal sequencing of regorafenib and TAS-102 for patients with mCRC; use of clinical characteristics to inform this decision
  • Research supporting the FDA approvals of pembrolizumab, nivolumab and nivolumab/ipilimumab for MSI-high mCRC; patient selection for anti-PD-1 monotherapy or combination therapy
  • Available and emerging research evaluating the use of combination BRAF/MEK/EGFR inhibition for patients with mCRC and BRAF V600E tumor mutations

Module 4: Therapeutic Decision-Making for Patients with Localized, Locally Advanced and Metastatic Pancreatic Adenocarcinoma (PAD)


  • Current role of chemotherapy, including FOLFIRINOX and gemcitabine/nab paclitaxel, in the neoadjuvant, adjuvant and metastatic settings
  • Importance of age, performance status and symptomatology in the selection of first-line therapy for patients with metastatic PAD
  • Management of side effects associated with currently available agents; palliative care considerations in advanced PAD
  • Mechanism of action of and available research data with nanoliposomal irinotecan (nal-IRI)
  • Integration of nal-IRI/5-FU/LV into the management of metastatic disease; patient education issues with the use of nal-IRI

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gastrointestinal (GI) cancers.

Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:

  • Apply available research data to the therapeutic and supportive care of patients with colorectal cancer (CRC), gastroesophageal cancer, pancreatic cancer and hepatocellular carcinoma (HCC).
  • Recognize the importance of biomarker analysis for patients diagnosed with CRC or gastric/gastroesophageal junction (GEJ)/esophageal cancer, and use this information to counsel these individuals regarding the selection of evidence-based systemic treatment options.
  • Describe the clinical indications, benefits and toxicities associated with the use of existing and recently approved systemic therapies in the management of metastatic CRC.
  • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to optimize systemic therapy for locally advanced or metastatic gastric/GEJ/esophageal cancer.
  • Consider age, performance status and other clinical and logistical factors in the selection of systemic therapy for patients with localized, locally advanced or metastatic pancreatic cancer.
  • Communicate the benefits and risks of approved and emerging systemic interventions to patients with locally advanced or metastatic HCC.
  • Appraise the rationale for and clinical data with commercially available and developmental immune checkpoint inhibitors in the treatment of GI cancers.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CME/CNE planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck and Taiho Oncology Inc.

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room: 
Grand Ballroom E-K (Lobby Level)

The Anaheim Marriott is the headquarters hotel for the 2019 ONS Congress and is conveniently located near the Anaheim Convention Center (0.2 miles).


Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 1 — Gastrointestinal Cancers. Onsite registration will be open starting at 10:45 AM on Wednesday, April 10, 2019. If you are interested in standing by for seating (day of the program), please visit our onsite registration desk located outside the Grand Ballroom (Lobby Level) at the Anaheim Marriott hotel (700 West Convention Way, Anaheim, CA 92802). You may arrive up to 45 minutes before the program start time and receive a standby ticket.

If seats become available for the program, we will accept standby registration on a first come, first served basis prioritized for oncology nurses treating patients. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at or call (800) 233-6153.